Overview

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Status:
Recruiting
Trial end date:
2023-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
I-Mab Biopharma Co. Ltd.
Collaborator:
I-Mab Biopharma Co. Ltd.
Treatments:
Pembrolizumab
Rituximab